Literature DB >> 21907093

Huntington's disease: clinical presentation and treatment.

Marianne J U Novak1, Sarah J Tabrizi.   

Abstract

Huntington's disease (HD) is a devastating inherited neurodegenerative disease characterized primarily by progressive motor, cognitive, and psychiatric symptoms. It is caused by autosomal dominant inheritance of an expanded CAG repeat within the Huntington's gene on chromosome 4. In this chapter, we characterize the typical and variant motor phenotypes of the disease and then proceed to describe the cognitive and psychiatric profile. We then give an overview of a suggested multidisciplinary approach to the management of HD, emphasizing the fact that it is a disease which impacts on entire families rather than affecting individuals in isolation. We then describe the pharmacological and nonpharmacological options available for management of specific symptoms.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21907093     DOI: 10.1016/B978-0-12-381328-2.00013-4

Source DB:  PubMed          Journal:  Int Rev Neurobiol        ISSN: 0074-7742            Impact factor:   3.230


  36 in total

Review 1.  Choosing an animal model for the study of Huntington's disease.

Authors:  Mahmoud A Pouladi; A Jennifer Morton; Michael R Hayden
Journal:  Nat Rev Neurosci       Date:  2013-10       Impact factor: 34.870

2.  Acetylcholinesterase inhibitors in cognitive impairment in Huntington's disease: A brief review.

Authors:  Joe John Vattakatuchery; Renjith Kurien
Journal:  World J Psychiatry       Date:  2013-09-22

3.  Vildagliptin Attenuates Huntington's Disease through Activation of GLP-1 Receptor/PI3K/Akt/BDNF Pathway in 3-Nitropropionic Acid Rat Model.

Authors:  Noha H Sayed; Nevine Fathy; Mona A Kortam; Mostafa A Rabie; Ahmed F Mohamed; Ahmed S Kamel
Journal:  Neurotherapeutics       Date:  2020-01       Impact factor: 7.620

4.  The differential diagnosis of Huntington's disease-like syndromes: 'red flags' for the clinician.

Authors:  Davide Martino; Maria Stamelou; Kailash P Bhatia
Journal:  J Neurol Neurosurg Psychiatry       Date:  2012-09-19       Impact factor: 10.154

5.  SIRT2 ablation has no effect on tubulin acetylation in brain, cholesterol biosynthesis or the progression of Huntington's disease phenotypes in vivo.

Authors:  Anna Bobrowska; Gizem Donmez; Andreas Weiss; Leonard Guarente; Gillian Bates
Journal:  PLoS One       Date:  2012-04-12       Impact factor: 3.240

6.  Genistein improves 3-NPA-induced memory impairment in ovariectomized rats: impact of its antioxidant, anti-inflammatory and acetylcholinesterase modulatory properties.

Authors:  Esther T Menze; Ahmed Esmat; Mariane G Tadros; Ashraf B Abdel-Naim; Amani E Khalifa
Journal:  PLoS One       Date:  2015-02-12       Impact factor: 3.240

7.  8OHdG is not a biomarker for Huntington disease state or progression.

Authors:  Beth Borowsky; John Warner; Blair R Leavitt; Sarah J Tabrizi; Raymund A C Roos; Alexandra Durr; Chris Becker; Cristina Sampaio; Allan J Tobin; Howard Schulman
Journal:  Neurology       Date:  2013-04-24       Impact factor: 9.910

8.  Genetic and Environmental Contributors to Neurodegeneration: An Exploration of the Effects of Alcohol on Clinical Features of Huntington's Disease Using the Enroll-HD Global Platform.

Authors:  Alexander L Symonds; Antonella Macerollo; Kevin Foy; Sundus H Alusi; Rhys Davies
Journal:  Int J Environ Res Public Health       Date:  2021-05-12       Impact factor: 3.390

9.  Impact of Chorea on Self-care Activity, Employment, and Health-care Resource Use in Patients with Huntington's Disease.

Authors:  Daniel O Claassen; Jonathan DeCourcy; Jennifer Mellor; Charlotte Johnston; Ravi G Iyer
Journal:  J Health Econ Outcomes Res       Date:  2021-06-21

10.  Unmet needs for healthcare and social support services in patients with Huntington's disease: a cross-sectional population-based study.

Authors:  Marleen R van Walsem; Emilie I Howe; Kristin Iversen; Jan C Frich; Nada Andelic
Journal:  Orphanet J Rare Dis       Date:  2015-09-28       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.